Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...

Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight ...

Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

The "U.S. Medical Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering. This report presents a complete picture of the medical weight loss market in the ...

Yahoo Finance will chronicle the latest news and updates on Trump's tariffs — from the threats to the eventual policy.

Yahoo Finance will chronicle the latest news and updates on Trump's tariffs — from the threats to the eventual policy.